# Ask whether survivorship screening saves lives, using registry-based randomisation

Source: https://onco.cc/ideas/idea-rejuv-registry-randomised-screening-in-survivors/  
OnCo record `idea-rejuv-registry-randomised-screening-in-survivors` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

No randomised trial has shown that screening survivors for a second cancer reduces death from it. A registry-based randomised trial, which invites rather than enrols, is the only design that could answer this at an affordable cost.

## Summary

Survivors of chest radiotherapy given young are offered breast surveillance in the United Kingdom on the strength of their measured risk. Survivors of the same treatment are offered nothing for lung, skin, bowel or bladder, despite measured excess risks, and the reason is not that anyone decided against it. A conventional trial here is impossible: the latency is decades, each survivor group is small, and consenting people to no surveillance when their risk is known is not acceptable.

A registry-based randomised design, as used in cardiology and in screening research, changes the economics. Eligible survivors are identified from a registry linkage, randomised to be invited or not invited to a surveillance pathway, and followed through the same registry for cancer incidence, stage at diagnosis and death. Nobody is denied care they would otherwise have had, because the comparator is the current default of no programme. The marginal cost is the invitation and the pathway, not a trial infrastructure.

The honest limits are that this answers the invitation question rather than the test question, that contamination from private screening would dilute the effect, and that mortality from a specific second cancer needs very large numbers or very long follow-up. Stage shift and interval cancers are the realistic interim endpoints.

## Fields

- Kind: Idea
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; open-problem; screening
- Hypothesis: Inviting a defined survivor group with a measured excess risk to an organised surveillance pathway reduces death from that cancer, or at minimum shifts stage at diagnosis, compared with the current default of no programme.
- Rationale: Measured excess risks in several survivor groups exceed the risk in populations for whom screening has been shown to save lives: second-primary lung cancer rates in survivors of some head and neck cancers exceed the rate in the control arm of the trial that established lung screening works. No country screens on the basis of treatment history. The only existing survivor programme, the United Kingdom's very high risk breast protocol, rests on inference rather than trial evidence, and that inference has never been tested in any organ.
- Proposed test: A registry-based randomised invitation trial in a country with linked cancer registry and treatment data: identify survivors meeting an exposure threshold, randomise to invitation or no invitation, and follow through the registry for incidence, stage distribution and cause-specific mortality. Start with lung after chest radiotherapy or thoracic treatment, where the comparator trial evidence in a non-survivor population already exists and the risk is highest.
- Maturity: speculative
- Actor: research

## Sources

- ClinicalTrials.gov NCT06113016: https://clinicaltrials.gov/study/NCT06113016
- NHS England: very high risk breast screening protocol: https://www.gov.uk/government/publications/breast-screening-very-high-risk-women-surveillance-protocols

## Connected records

- terms: [Lung cancer after chest radiotherapy and after alkylating chemotherapy](https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/), [Screening survivors: where the UK, American and European answers differ](https://onco.cc/terms/rejuv-second-screening-after-treatment-compared/), [The UK very high risk breast screening protocol after chest radiotherapy](https://onco.cc/terms/rejuv-second-uk-very-high-risk-breast-screening/)
- ideas: [Tailored screening for second cancers in survivors with known high-risk exposures](https://onco.cc/ideas/idea-acc-tailored-second-cancer-screening/)
- roadmaps: [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- bottlenecks: [No randomised trial shows that any survivorship screening programme reduces death](https://onco.cc/bottlenecks/rejuv-agenda-screening-without-a-trial/), [Registries count diagnoses and deaths, and not what treatment left behind](https://onco.cc/bottlenecks/rejuv-agenda-late-effects-are-not-counted/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)

---
JSON: https://onco.cc/api/v1/entities/idea-rejuv-registry-randomised-screening-in-survivors.json